BioSpace News Archive

Positive topline results from the pivotal DESTINY-Breast04 phase 3 trial showed ENHERTU® demonstrated a statistically significant and clinically meaningful improvement in both progression-free survival and overall survival in patients with HER2 low unresectable and/or metastatic breast cancer regardless of hormone receptor status versus physician’s choice of chemotherapy, which is the current standard of care.

OMass Therapeutics is pleased to confirm that it will be presenting at a number of upcoming banking, business and scientific conferences, as detailed below.

The “Microfluidics to Address Pandemics - SARS-CoV-2 and Beyond” training has been added to ResearchAndMarkets.com’s offering.

Enzolytics, Inc. (OTC PINK:ENZC) (https://enzolytics.com/) announces its plans for entry into the diagnostics market.

The global liquid biopsy market is projected to gain momentum from the increasing cases of cancer worldwide.

The joint reconstruction devices market expects to observe a stable growth trajectory across the assessment period of 2017-2025.

The recent developments in medical sector such as invisible devices, and minimally invasive surgeries are the key factors promoting the growth of the global bone conduction hearing devices market.

Dr. Jorge Gallardo Ballart has announced in the Board of Directors’ session on Friday 18th February, his intention to retire from his positions of Chairman of the Board of Directors and Board member with effect as of the end of the General Shareholders Meeting of Almirall, S.A. that will take place next 6 May 2022.

Prestige BioPharma Limited, a Singapore-based biopharmaceutical with operations in USA and South Korea, announced that the manufacturing facility for its Herceptin® biosimilar, Tuznue®, in Prestige Biologics Co., Ltd., has received European Union Good Manufacturing Practices certification.

Regulatory authorities of China have approved the mixing of domestic inactivated vaccines against COVID and use of a different vaccine, including adenoviral-based, as booster shot providing yet another confirmation of the efficacy of mix & match approach pioneered by the Russian Sputnik V vaccine in creating a stronger and more durable immunity, including against the Omicron variant.